Marshall Wace, LLP Tricida, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $2.25 Million - $3.59 Million	264,174 Added 1127.55%	287,603 $3.02 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $471,385 - $764,147	-64,485 Reduced 73.35%	23,429 $227,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $646,167 - $934,525	87,914 New	87,914 $721,000
Q2 2021 Aug 13, 2021	SELL	$3.95 - $5.41 $407,963 - $558,755	-103,282 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $466,834 - $805,599	103,282 New	103,282 $546,000
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $531,654 - $1.15 Million	-121,660 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $1.04 Million - $3.28 Million	121,660 New	121,660 $1.1 Million
Q2 2019 Aug 14, 2019	SELL	$31.16 - $39.46 $2.05 Million - $2.6 Million	-65,912 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$19.96 - $38.62 $1.32 Million - $2.55 Million	65,912 New	65,912 $2.55 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.